KNSA vs JBTM Comparison

Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.

JBT Marel Corp operates through two reportable segments: Protein Solutions and Prepared Food and Beverage Solutions. The Protein Solutions segment includes businesses that provide solutions for the initial stage processing and harvesting of animal proteins, mainly focusing on poultry, pork, fish, and beef. The Prepared Food and Beverage Solutions segment includes businesses that offer solutions predominantly for downstream value-added preparation, preservation, and packaging of foods and beverages into ready-to-eat or drink products. This segment will also include capabilities for pet food, dairy, bakery, pharmaceutical, nutraceutical, and warehouse automation end markets. The majority of its revenue is generated from the Prepared Food and Beverage Solutions segment.